Ajanta Pharma is a specialty pharmaceutical company that makes finished medicines - tablets, capsules, ointments, and sterile eye drops - and sells them in over 30 countries across branded generics, US generics, and institutional antimalarial channels. Founded in 1979, the company has spent decades building a business that is deliberately diversified across geographies and therapies so that when one market faces headwinds, others step forward. The recurring approach is to target niches where it can be first or among the best - first-to-market launches in India, complex generics with limited competition in the US, and leadership positions in ophthalmology and dermatology - rather than competing on volume alone. # Business segments Four engines serving different customers from the same manufacturing backbone - a domestic branded-generics franchise built on chronic therapies, two international branded-generics businesses across Asia and Africa, and a selective US generics operation that prizes complexity over commodity scale. ## 1. India branded generics: the anchor franchise **A 3,750-strong field force promotes 350-plus branded medicines directly to doctors, with chronic therapies providing predictable, recurring demand and first-to-market launches creating pricing power.** - **Prescribed, not advertised** - medical representatives call on more than 250,000 doctors across India, conducting continuous medical education programmes and digital outreach to build brand loyalty at the prescription pad. The company decides the product, the price, and the promotion; distributors simply deliver the goods for a fee. - **Chronic therapies dominate** - over 65% of the India portfolio treats long-term conditions like heart disease, eye disorders, and skin ailments, so patients refill prescriptions month after month rather than buying once and stopping. Cardiology alone accounts for 37% of India sales, ophthalmology 29%, and dermatology 22%. - **First-to-market is the edge** - roughly half the portfolio consists of generics that Ajanta was the first to launch in the country, which means it captures market share before competitors arrive and builds brand recognition that outlasts price erosion. In FY26 alone, it launched 26 new products including five first-time launches in India. - **Rankings tell the story** - as of March 2026, Ajanta ranked 24th in the overall Indian Pharmaceutical Market and 2nd in ophthalmology, having gained ground from 26th in prior years. The India business has consistently grown faster than the broader market, outperforming IPM growth by over 300 basis points in FY26. - **New therapies widen the funnel** - the company recently entered gynaecology and nephrology, two fresh therapeutic segments that expand the addressable patient base beyond its traditional strongholds. It also made its first-ever brand acquisition, buying three pain-management brands in FY25. ## 2. Asia branded generics: the chronic-care exporter **The same doctor-promotion model, exported to nearly a dozen countries across the Middle East, Southeast Asia, and Central Asia, with a portfolio that is 75% chronic therapies.** - **Own feet on the ground** - Ajanta deploys its own medical representatives in every Asian market it enters, rather than relying on local distributors to do the selling, so it controls the brand message and the doctor relationship directly. The combined Asia-Africa field force exceeded 2,250 representatives in FY26, with 250 added during the year. - **Chronic, not acute** - about three-quarters of the 250-plus products in Asia treat long-term conditions such as cardiac disease, diabetes, and respiratory illness, mirroring the India playbook of predictable refill-driven demand. - **Leadership in narrow lanes** - the company holds leadership positions in many molecules and sub-therapeutic segments across these markets, meaning it dominates specific drug categories even where it is not the largest overall player. It executes what management calls "very clinically" to post superior growth relative to the markets it operates in. - **Portfolio depth through launches** - 15 new products were introduced in Asia during FY26, largely in chronic therapies, following a record combined launch year in FY25 when 70 products were rolled out across India and emerging markets together. ## 3. Africa branded generics: the continent-wide footprint **A 21-country branded-generics presence built on the same direct-promotion model, with leadership positions in many of the markets where it competes.** - **Breadth over concentration** - the Africa business spans 21 countries with 250-plus products across eight therapeutic segments, making it a portfolio of small-to-medium markets rather than a bet on any single economy. The company is among the top 10 players in many of these markets. - **Shared sales force, local execution** - the same field-force team that covers Asia also covers Africa, with representatives promoting directly to doctors in each country rather than relying on third-party distributors to generate demand. - **Steady new introductions** - eight new products were launched in Africa during FY26, adding to a portfolio that already holds leadership positions in multiple molecules and sub-therapeutic segments. ## 4. US generics: the complexity play **A selective portfolio of 49 commercialised generics where difficult manufacturing or regulatory barriers keep competition low - sold through distributors who have named Ajanta their best overall generic manufacturer five times.** - **Complex, not commodity** - the US strategy deliberately avoids broad commodity generics in favour of products that are difficult to manufacture or have other barriers to entry, so price erosion is less savage than in high-competition molecules. The company describes its US execution as "excellent and flawless". - **Distributor relationships are the channel** - Ajanta sells through standard US pharmaceutical distribution networks and has been recognised as a preferred partner, receiving the DIANA Award as Best Overall Generic Manufacturer for the fifth time and a Manufacturer Partner of the Year Award from its key distribution partner Cencora. - **A pipeline, not just a shelf** - beyond the 49 products already commercialised, the company had 49 active ANDAs (abbreviated new drug applications) and 19 pending approvals with the US FDA as of FY26-end, providing a visible launch runway. Three new products were launched during the year. - **Price erosion is the headwind** - the US generics market is shaped by price declines, which had been severe at 15% to 18% in earlier periods but subsequently stabilised toward a more normal range of 5% to 8%. The market itself is projected to grow from roughly USD 146 billion in 2025 to about USD 244 billion by 2035, driven by patent expirations and a shift toward complex generics. ## 5. Africa institutional antimalarials: the legacy lifeline **A tender-driven business supplying WHO-pre-qualified antimalarial tablets to aid agencies - unpredictable by nature, and deliberately shrunk to just 3% of revenue.** - **Over a billion patients treated** - Ajanta was the first generic company to obtain WHO pre-qualification for antimalarials, and its Artemether & Lumefantrine tablets have reached more than one billion patients through multilateral aid programmes. - **Lumpy and unpredictable** - sales depend entirely on the availability of funds with procurement agencies and the timing of sponsor procurement cycles, making the business impossible to forecast with precision. Revenue can swing sharply: the Africa Institutional business declined 41% in FY25 alone. - **Deliberately downsized** - the company has consciously reduced its reliance on this segment from 10% of revenue in FY21 to 3% in FY26, redirecting focus toward the more predictable branded-generics and US businesses. # Manufacturing and R&D backbone **Seven plants in India - two approved by the US FDA - and an 850-scientist R&D centre supply every geography from a single, quality-controlled engine.** - **Own the factories** - all seven manufacturing facilities are company-owned, producing tablets, capsules, ointments, powders, liquids, and sterile eye drops, which reduces dependency on third-party suppliers and ensures quality control across every market. Two facilities at Paithan and Dahej are US FDA-approved; the rest are WHO cGMP-compliant. - **R&D as the product pipeline** - more than 850 scientists work from a 100,000-square-foot research centre in Mumbai, developing complex formulations using advanced drug-delivery systems and handling everything from analytical development to regulatory affairs. R&D spending was ₹252 crore in FY26, representing 5% of revenue. - **Supply reliability above 95%** - the supply chain is designed to ensure no stock-out of any product in any market, even for a single day, supported by digital tools, diversified sourcing, and optimised inventory management. Inventory days improved to 63 in FY26 from 72 the year before. - **Sustainability built into operations** - all plants operate with zero liquid discharge, recycling 100% of wastewater, and nearly 90% of hazardous waste is recycled through co-processing for the cement industry. A 12.6-megawatt captive solar plant supplied 34% of total energy needs in FY25, with a target of 70% green energy in the coming year. # Group structure and partners **A listed Indian parent with five wholly owned overseas subsidiaries - the largest in the US handles nearly all American sales - and no joint ventures or associate companies.** - **US subsidiary is the heavyweight** - Ajanta Pharma USA Inc., a 100% subsidiary, generated turnover of ₹1,505.74 crore in FY26, and more than 10% of the parent company's revenue comes from sales to this entity. - **Three other active subsidiaries** - wholly owned units in the Philippines (turnover ₹292.72 crore), Mauritius (₹150.89 crore), and a newly incorporated entity in Ireland established during FY26 for future pharmaceutical business. The Nigeria subsidiary remains dormant with nil turnover. - **A legacy plant closed** - the Mauritius subsidiary previously operated a manufacturing facility for about 25 years, but it was shut during FY22 because it needed major capital expenditure that was commercially unviable; all supplies are now met from India. - **A digital-health side bet** - in April 2021, Ajanta took a 4.03% partnership interest in ABCD Technologies LLP (to be renamed IndoHealth Services LLP) for ₹25 crore, an entity that invests in companies aiming to digitise India's healthcare infrastructure in support of the National Digital Health Mission.